PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q1–2025Q4) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Y2 Solution, expanding beyond its core power supply unit (PSU) business into robotics system integration, bioenergy, and biotech, has shown a quarterly earnings recovery in 2026 after turning to a loss in 2025.
Consolidated 2025 revenue rose year over year, but the company swung to an operating and net loss due to new-business investment and derivative valuation losses.
Operating profit turned positive in Q1 2026, and owner net income also turned positive in Q2 2026.
The bioenergy (biodiesel trading) segment, which began contributing meaningfully from Q4 2025, has emerged as a key growth driver.
Robotics system integration through subsidiary HRT Robotics and the dry AMD cell therapy from US joint venture Luxa (FDA RMAT designated) are being pursued in parallel as new growth pipelines.
With multiple new businesses advancing simultaneously, execution capability, capital allocation, and the smooth progress of clinical and order schedules are key points to watch.
Y2 Solution originated in 1976 as a chemical trading business, entered the electronics sector in 1985, listed on the KOSPI in 1995, and came under new management following Deokwoo Electronics' acquisition in 2021.
Its core business is manufacturing power supply units (PSU) for LCD, LED, OLED, UHD TVs and EV fast chargers, which has long accounted for a substantial share of revenue. A chemical wholesale business handling petrochemical intermediates and solvent cleaners has served as a stable cash-generating segment.
Diversification has accelerated recently: in July 2025 the company acquired a stake in robotics system integrator HRT Robotics, entering the robotics business. The company has stated a goal for HRT Robotics to achieve roughly 50 billion won in revenue through capacity expansion.
HRT Robotics is the domestic partner of Universal Robots, the global leader in collaborative robots, with more than a decade of design and operations-focused SI experience.
In biotech, the company holds a 50% stake in Luxa Biotechnology, established jointly with the US National Stem Cell Institute (NSCI) in 2019, which is developing a cell therapy for dry age-related macular degeneration.
Since the second half of 2025, a bioenergy business centered on biodiesel trading using feedstocks such as soybean oil, used cooking oil, and animal fats has been added, forming a diversified portfolio spanning PSU, chemicals, robotics, biotech, and bioenergy.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩32.1B | -₩1.4B | −4.4% |
| 2025Q3 | — | — | — |
| 2025Q4 | ₩48.3B | -₩1.2B | −2.4% |
| 2026Q1 | ₩86.7B | ₩1B | 1.1% |
| 2026Q2 | ₩87.4B | ₩700M | 0.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩120.5B | ₩1.8B | -₩2.2B | 1.5% | −2.7% | 53.5% |
| 2023 | ₩136.9B | ₩1.9B | -₩300M | 1.4% | −0.3% | 21.7% |
| 2024 | ₩154.5B | ₩2.9B | ₩6.6B | 1.9% | 6.1% | 15.0% |
| 2025 | ₩165.1B | -₩2.6B | -₩9.6B | −1.6% | −9.7% | 49.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
Consolidated revenue for 2025 rose 7.3% year over year to 165.06 billion won from 154.51 billion won in 2024, but operating profit swung to a loss of 2.57 billion won and owner net income to a loss of 9.59 billion won.
This contrasts with 2024, when the company posted 154.5 billion won in revenue with 2.89 billion won in operating profit and 6.58 billion won in net profit.
In 2023 revenue was 136.94 billion won with operating profit of 1.91 billion won but a small net loss of 0.35 billion won, while 2022 revenue was 120.52 billion won with operating profit of 1.78 billion won and a net loss of 2.21 billion won—meaning operating profit stayed positive for several years before turning negative for the first time in 2025.
On a quarterly basis, Q2 2025 revenue was 32.07 billion won with an operating loss of 1.40 billion won and a net loss of 4.83 billion won, and Q4 2025 revenue rose to 48.30 billion won but losses continued, with an operating loss of 1.17 billion won and a net loss of 4.52 billion won.
Revenue then jumped sharply to 86.66 billion won in Q1 2026, with operating profit turning positive at 0.95 billion won, though net income remained negative at -0.65 billion won; in Q2 2026, revenue reached 87.37 billion won, operating profit was 0.67 billion won, and owner net income also turned positive at 0.45 billion won.
The company attributed the 2025 net loss to a derivative valuation loss on convertible bonds tied to the rising share price, stating no actual cash outflow occurred.
The sharp revenue increase and earnings improvement in the first half of 2026 are mainly attributed to expanding contributions from the bioenergy business, which began generating meaningful revenue from Q4 2025.
The PSU business operates in a mature display and lighting power supply market, offering steady cash flow rather than high growth, and has recently expanded into power modules for EV fast chargers.
The chemical distribution business, which supplies imported raw materials from China and Japan to domestic buyers, is exposed to economic cycles but provides a relatively stable revenue base.
Regarding the robotics SI market, Hanyang Securities assessed that Korea has structural automation demand given its low process automation rate relative to robot deployment density.
HRT Robotics is positioned differently from a simple robot manufacturer, leveraging its verified SI capability through a domestic partnership with Universal Robots, the global leader in collaborative robots.
The bioenergy segment operates in a policy-driven market, with Korea's mandatory biodiesel blending ratio for marine diesel set to rise to 5% by 2030 and the United States applying differentiated ratios of 2% to 20% by state, while tightening European environmental policy is also cited as a demand driver.
In biotech, the dry AMD therapy being developed by Luxa targets a market estimated at roughly 40 trillion won globally, an area with significant unmet medical need given the current absence of treatments that restore lost vision.
The company has stated a goal of expanding bioenergy segment revenue to more than 200 billion won in 2026, positioning it as a core cash-generating business. It has already begun exports to the United States, and analysts note that entry into the European market could further widen earnings improvement.
In robotics, the company is advancing next-generation drivetrain technology based on axial flux permanent magnet (AFPM) motors through a partnership with deep-tech firm Wizzin, targeting an ultra-low-profile autonomous mobile robot (AMR) prototype unveiling within 2026.
In biotech, Luxa's dry AMD therapy has entered its final cohort (Cohort 3) evaluating maximum dosage, and the company has stated it is supporting development toward completing the Phase 1/2a trial and securing topline data within 2026.
Hanyang Securities noted the company is reviewing a global pharma license-out as its priority strategy after trial completion, assessing that the RMAT designation could serve as a premium factor in license-out negotiations.
These plans, however, represent company targets and analyst projections, and actual achievement will need to be confirmed through future disclosures and clinical or order outcomes.
The current share price trades above the company's net asset value, reflecting a certain premium to book value.
Operating profit was generally positive from 2022 through 2024 before turning to a loss for the first time in 2025, and the first half of 2026 has shown a sequential shift back toward positive operating profit and net income, indicating an improving earnings trajectory.
However, given significant profit volatility in recent years, multiple comparisons based on historical earnings should be treated as a limited reference point.
The company currently pays no dividend, suggesting that market pricing is driven more by growth expectations in the new robotics, biotech, and bioenergy businesses than by dividend appeal.
Hanyang Securities assessed that a valuation re-rating is possible based on the completed biotech equity investment and robotics M&A, but did not provide a specific investment rating or price target.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
The company is expanding from its PSU and chemical distribution core into robotics SI, bioenergy, and biotech. HRT Robotics, a domestic partner of Universal Robots, has set a revenue target of roughly 50 billion won based on its verified SI capability.
The bioenergy business began generating meaningful revenue from Q4 2025, reaching 45 billion won for the year, with a 2026 target of more than 200 billion won.
After consecutive operating and net losses from Q2 to Q4 2025, the trend reversed with operating profit turning positive in Q1 2026 and owner net income also turning positive in Q2 2026.
Revenue also jumped from 48.3 billion won in Q4 2025 to 86.7 billion won in Q1 2026 and 87.4 billion won in Q2 2026, mainly attributed to bioenergy segment expansion.
The dry AMD cell therapy from US joint venture Luxa has received FDA RMAT designation and is in its final maximum-dose evaluation cohort within Phase 1/2a trials.
The company aims to complete the trial and secure topline data within 2026, and Hanyang Securities noted a global pharma license-out is being reviewed as the priority strategy afterward, with the RMAT designation potentially serving as a premium factor in negotiations.
While 2025 revenue grew, both operating profit and net income turned negative. The net loss reflects a derivative valuation loss on convertible bonds, meaning similar non-cash earnings swings could recur depending on future share price movements.
Given that the operating profit trend maintained from 2022 to 2024 broke down within a single year in 2025, earnings stability needs further confirmation.
The company is simultaneously pursuing three fundamentally different new businesses—robotics SI, bioenergy, and biotech—raising the possibility that management resources and capital become spread thin.
HRT Robotics' revenue target and the bioenergy segment's 200-billion-won goal are company-stated plans, with multiple execution variables such as order intake and distribution network expansion remaining before actual achievement.
While Luxa's dry AMD therapy may benefit from faster development timelines due to the RMAT designation, this does not guarantee approval, and the risk remains that Phase 1/2a results could fall short of expectations. License-out negotiations could also be delayed or fail depending on counterparty terms and timing.
A significant portion of the 2025 net loss stemmed from a derivative valuation loss on convertible bonds, a structural feature where non-cash losses expand as the share price rises. There is also potential equity dilution if the bonds are converted.
Funding needs and changes in financial structure from expanding new-business investment also warrant ongoing monitoring.
Luxa's dry AMD therapy remains in Phase 1/2a trials, and commercialization prospects cannot be assumed until final efficacy and safety data are secured. Trial delays or unexpected results could also disrupt the license-out strategy.
If synergy between the existing PSU and chemical businesses and the new robotics, bioenergy, and biotech ventures does not materialize as planned, returns on investment could be delayed.
The bioenergy business is exposed to raw material (soybean oil, used cooking oil, etc.) price fluctuations and policy changes across countries, which could create volatility in revenue and margins.
The Q3 2026 quarterly report is expected around this time, and it will be important to check whether the bioenergy revenue expansion and earnings improvement trend continued into the third quarter.
It will be important to check whether the company achieves its stated goal of completing Luxa's Phase 1/2a trial and releasing topline data.
The schedule for unveiling the ultra-low-profile AMR prototype through the HRT Robotics and Wizzin collaboration, and actual order results, should be monitored.
The actual achievement of the company's stated bioenergy revenue target of more than 200 billion won and progress on European market entry should be confirmed.
Y2 Solution is in a transitional phase, building three new growth pillars—robotics SI, bioenergy, and biotech—on top of its long-standing PSU and chemical distribution businesses.
In 2025, despite revenue growth, both operating and net income turned negative due to new-business investment and a convertible bond derivative valuation loss, but the first half of 2026 showed a sequential turnaround with operating profit and then owner net income both turning positive.
Bioenergy revenue expansion has served as the core driver of the near-term earnings improvement, while the robotics and biotech segments underpin the mid- to long-term growth narrative through HRT Robotics' SI capability and Luxa's FDA RMAT-designated pipeline, respectively.
However, the execution burden of pursuing three new businesses simultaneously, non-cash earnings volatility tied to convertible bonds, and clinical uncertainty are factors that warrant continued attention.
The sustainability of quarterly earnings, Luxa's clinical topline data, and achievement of the bioenergy revenue target are likely to be the key variables determining the success of this business transformation.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.